Gilead Sciences Inc GILD:NASDAQ

Last Price$62.86NASDAQ Previous Close - Last Trade as of 4:00PM ET 9/23/22
NASDAQ 15-minute delayed Bid/Ask Quotes
Today's Change0(0.00%)
Bid (Size)$62.94 (1)
Ask (Size)$63.10 (3)
Day Low / HighN/A - N/A
Volume7.6 M
 

View Biotechnology IndustryPeer Comparison as of 09/23/2022

 

Gilead Sciences Inc ( NASDAQ )

Price: $62.86
Change: -0.91 (1.43%)
Volume: 7.6 M
4:00PM ET 9/23/2022
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Moderna Inc ( NASDAQ )

Price: $123.64
Change: -0.68 (0.55%)
Volume: 3.9 M
4:00PM ET 9/23/2022
 
 

Amgen Inc ( NASDAQ )

Price: $226.97
Change: -0.78 (0.34%)
Volume: 2.1 M
4:00PM ET 9/23/2022
 
 

Illumina Inc ( NASDAQ )

Price: $190.38
Change: -3.11 (1.61%)
Volume: 1.3 M
4:00PM ET 9/23/2022
 

Read more news Recent News

Gilead Sciences Completes Acquisition of MiroBio for $405 Million
4:37PM ET 9/20/2022 MT Newswires

Gilead Sciences (GILD) said Tuesday it has completed the acquisition of privately held UK biotech company MiroBio for about $405 million in cash. The...

Sector Update: Health Care Stocks Mixed Premarket Friday
9:17AM ET 9/16/2022 MT Newswires

Health care stocks were mixed premarket Friday, with the Health Care SPDR (XLV) down 0.63% and the iShares Biotechnology Index (IBB) inactive. AstraZeneca...

Gilead Sciences Says Veklury Gets Positive CHMP Opinion to Widen Indication to Treat Pediatric Patients With COVID-19
7:35AM ET 9/16/2022 MT Newswires

Gilead Sciences (GILD) said Friday the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion to widen...

Gilead Says WHO Expands Recommendation for Veklury to Patients with Severe COVID-19
4:08AM ET 9/16/2022 MT Newswires

Gilead Sciences (GILD) said Thursday the World Health Organization's COVID-19 guidelines conditionally recommend Veklury, or remdesivir, for the treatment...

View all Commentary and Analysis

Dividend Champion, Contender, And Challenger Highlights: Week Of September 25
12:55AM ET 9/25/2022 Seeking Alpha

Top Research Reports for Union Pacific, AT&T & Blackstone
12:51PM ET 9/23/2022 Zacks

Today's Research Daily features new research reports on 16 major stocks, including Union Pacific...

Cryoport: A Rare Investing Opportunity
7:11PM ET 9/22/2022 Seeking Alpha

NuCana: An Intriguing 'Sum Of The Parts' Story
3:40PM ET 9/22/2022 Seeking Alpha

Company Profile

Business DescriptionGilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA. View company web site for more details
Address333 Lakeside Drive
Foster City, California 94404
Phone+1.650.574.3000
Number of Employees11,000
Recent SEC Filing09/12/20228-K
Chairman & Chief Executive OfficerDaniel P. O'Day
Chief Financial OfficerAndrew D. Dickinson
Chief Medical OfficerMerdad V. Parsey
Executive Vice President-ResearchFlavius Martin

Company Highlights

Price Open$63.49
Previous Close$63.77
52 Week Range$57.17 - 74.12
Market Capitalization$78.8 B
Shares Outstanding1.3 B
SectorHealth Technology
IndustryBiotechnology
Current Dividend / Yield$0.73 / 4.65%
Dividend Ex-Date09/14/2022
Dividend Pay-Date09/29/2022
Dividend Yield 5 Year Average3.80%
Next Earnings Announcement10/27/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings19.16
Earnings per Share$5.68
Beta vs. S&P 500N/A
Revenue$22.2 B
Net Profit Margin15.06%
Return on Equity20.01%

Analyst Ratings as of 09/11/2022

Buy
8
Overweight
1
Hold
19
Underweight
0
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset